U.S. Markets closed

  • S&P 500

    3,923.68
    -165.17 (-4.04%)
     

  • Dow 30

    31,490.07
    -1,164.52 (-3.57%)
     

  • Nasdaq

    11,418.15
    -566.37 (-4.73%)
     

  • Russell 2000

    1,774.85
    -65.45 (-3.56%)
     

  • Crude Oil

    109.30
    -3.10 (-2.76%)
     

  • Gold

    1,815.10
    -3.80 (-0.21%)
     

  • Silver

    21.40
    -0.35 (-1.61%)
     

  • EUR/USD

    1.0466
    -0.0089 (-0.8477%)
     

  • 10-Yr Bond

    2.8860
    -0.0820 (-2.76%)
     

  • Vix

    30.96
    +4.86 (+18.62%)
     

  • GBP/USD

    1.2348
    -0.0144 (-1.1546%)
     

  • USD/JPY

    128.1710
    -1.1870 (-0.9176%)
     

  • BTC-USD

    29,185.31
    -926.44 (-3.08%)
     

  • CMC Crypto 200

    650.57
    -20.11 (-3.00%)
     

  • FTSE 100

    7,438.09
    -80.26 (-1.07%)
     

  • Nikkei 225

    26,911.20
    +251.45 (+0.94%)
     

Nitric Oxide Synthase Inhibitor Pipeline Research Report 2021: Comprehensive Insights About 5+ Companies and 5+ Pipeline Drugs - ResearchAndMarkets.com

·4 min read

DUBLIN, November 30, 2021--(BUSINESS WIRE)--The "Nitric Oxide Synthase Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "Nitric oxide synthase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Nitric oxide synthase inhibitors pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nitric oxide synthase inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Nitric oxide synthase inhibitors.

Nitric oxide synthase inhibitors Emerging Drugs Chapters

This segment of the Nitric oxide synthase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nitric oxide synthase inhibitors Emerging Drugs

VAS203: Vasopharm BIOTECH

VAS203 is an analogue of the natural co-factor biopterin, which is involved in the generation of nitric oxide by the Nitric Oxide Synthase (NOS) family of enzymes. The mechanism of action of VAS203 is believed to confer selective down regulation of inducible NOS (iNOS) without significantly inhibiting the function of other NOS enzymes.

Vasopharm's ronopterin (VAS203) missed its primary endpoint in the Phase III NOSTRA III study in patients with traumatic brain injury, but further analyses point to a significant clinical benefit when the inducible NOS inhibitor is given within 12 hours of trauma.

Nitric oxide synthase inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Nitric oxide synthase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nitric oxide synthase inhibitors

There are approx. 5+ key companies which are developing the therapies for Nitric oxide synthase inhibitors. The companies which have their Nitric oxide synthase inhibitors drug candidates in the most advanced stage, i.e. phase III include Vasopharm BIOTECH.

Key Questions Answered

  • How many companies are developing Nitric oxide synthase inhibitors drugs?

  • How many Nitric oxide synthase inhibitors drugs are developed by each company?

  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nitric oxide synthase inhibitors?

  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nitric oxide synthase inhibitors therapeutics?

  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

  • What are the clinical studies going on for Nitric oxide synthase inhibitors and their status?

  • What are the key designations that have been granted to the emerging drugs?

Companies Mentioned

  • EyePoint Pharmaceuticals

  • Reata Pharmaceuticals

  • vasopharm BIOTECH

  • Yiviva

  • NeurAxon

  • Neurophyxia

  • SaNOtize Research and Development

  • MediciNova

Key Topics Covered:

Introduction

Executive Summary

Nitric oxide synthase inhibitors: Overview

  • Causes

  • Mechanism of Action

  • Signs and Symptoms

  • Diagnosis

  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type

  • Assessment by Stage and Product Type

  • Assessment by Route of Administration

  • Assessment by Stage and Route of Administration

  • Assessment by Molecule Type

  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

VAS203: Vasopharm BIOTECH

  • Product Description

  • Research and Development

  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

2-iminobiotin: Neurophyxia

  • Product Description

  • Research and Development

  • Product Development Activities

Inactive Products

  • Comparative Analysis

Nitric oxide synthase inhibitors Key Companies

Nitric oxide synthase inhibitors Key Products

Nitric oxide synthase inhibitors- Unmet Needs

Nitric oxide synthase inhibitors- Market Drivers and Barriers

Nitric oxide synthase inhibitors- Future Perspectives and Conclusion

Nitric oxide synthase inhibitors Analyst Views

Nitric oxide synthase inhibitors Key Companies

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/qdg7hb

View source version on businesswire.com: https://www.businesswire.com/news/home/20211130005532/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Recommended Stories

  • Cisco reports big revenue miss, cuts full-year guidance

    Yahoo Finance's Jared Blikre joins the Live show to check out Cisco's mixed Q3 earnings report.

  • ‘It’s so horrible that I want to buy it’ — Jim Cramer likes these 2 beaten-down tech names that are still posting white-hot revenue growth

    High-quality items seldom go on sale. Grab them when they do.

  • This is how much money Americans think they need to be considered wealthy

    Charles Schwab's annual Modern Wealth Survey also asked 1,000 Americans how much they needed in order to live comfortably.

  • Here's Why Upstart Soared on Wednesday While Most Stocks Fell

    In contrast to the overall market, lending technology company Upstart Holdings (NASDAQ: UPST) was a major outperformer, with shares rising by about 6%. Upstart recently plunged by more than 50% after its first-quarter earnings, and the biggest reason was that the dollar amount of loans carried on Upstart's balance sheet more than doubled. Recently, Upstart's management has made it clear that it understands investors' concerns and is going to immediately take steps to address them.

  • Why Costco, Kohl's, and Five Below Were All Sliding Today

    Retail stocks including Costco (NASDAQ: COST), Kohl's (NYSE: KSS), and Five Below (NASDAQ: FIVE) were getting shocked today after retail giants including Walmart and Target badly missed bottom-line estimates and their first-quarter earnings reports. Both companies also cut their guidance for the year, warning that challenges from inflation and supply chain disruptions would persist. As of 11:05 a.m. ET, Costco stock was down 11.4%, while Kohl's had given up 10%, and Five Below was off 9.1%.

  • A ‘summer of pain’? The Nasdaq Composite could plunge 75% from peak, S&P 500 skid 45% from its top, warns Guggenheim’s Scott Minerd.

    The carnage playing out in the U.S. stock market on Wednesday is likely an amuse-bouche compared with the devastation on the menu for the bulls in the coming months and years, Guggenheim Partners Global Chief Investment Officer Scott Minerd told MarketWatch in an interview. The prominent CIO on Wednesday said he envisioned the possibility of a dreadful summer and fall for stock-market investors — one in which the Nasdaq Composite Index (COMP) eventually unravels, plunging 75% from its Nov. 19, 2021, peak (currently it’s down around 28%) and the S&P 500 (SPX) tumbles 45% from its Jan. 3, 2022, peak (from which presently down 18%) as we head into July. “That looks a lot like the collapse of the internet bubble,” Minerd said, referring to the implosion of technology stocks in 1999 and early 2000.

  • UPDATE: P&G closes downtown Cincinnati offices over 'security concern'

    UPDATE (May 18, 12:24 p.m.): The Cincinnati Police Department issued a statement that it is involved in an ongoing, multi-jurisdictional investigation and nobody has yet been charged. Cincinnati-based Procter & Gamble has closed its downtown offices on Wednesday over a reported security concern. A spokesperson for P&G (NYSE: PG) on Wednesday morning confirmed the closure of the company's downtown headquarters.

  • Can Nvidia Make a Rebound Rally Ahead of Earnings?

    Let's drill down on the technical indicators and charts to see how traders may be positioned. Our advice was hopefully helpful but now that prices reached our $164 downside price target from the Point and Figure chart maybe a new strategy is needed in the short-run. The trading volume has been very active since November.

  • Why Apple Stock Is Falling Today

    Shares of Apple (NASDAQ: AAPL) were falling 3.9% heading into noontime trading Wednesday as retail sector earnings have been weaker than expected this week and the Federal Reserve is expected to further tighten the screws on the economy. There has also been an uptick in cases of COVID-19, which caused Apple to delay implementation of its three-days-in-the-office policy.

  • Why Boeing and Airline Stocks Are Falling Today

    On Tuesday, airline stocks got a lift after United Airlines Holdings (NASDAQ: UAL) said that so far, at least, demand is holding up well in the face of rising inflation. Shares of United, American Airlines Holdings (NASDAQ: AAL), and Spirit Airlines (NYSE: SAVE) all fell about 5%, and planemaker Boeing (NYSE: BA) also traded down by a similar amount. As I said yesterday, these are volatile times to be investing in airline stocks.

  • Tesla cut from S&P 500 ESG Index, and Elon Musk tweets his fury

    (Reuters) -An S&P Dow Jones Indices executive told Reuters on Wednesday it has removed electric carmaker Tesla Inc from the widely followed S&P 500 ESG Index because of issues including claims of racial discrimination and crashes linked to its autopilot vehicles, and Tesla CEO Elon Musk responded with harsh tweets including that "ESG is a scam". In it changes, effective May 2, the sustainability index also added soon-to-be-Musk-controlled Twitter Inc and oil refiner Phillips 66 while dropping Delta Air Lines and Chevron Corp, according to an announcement. The back-and-forth over the index changes reflects a wider debate about the metrics used to judge corporate performance on environmental, social and governance (ESG) issues, a growing area of investing.

  • Why Nio Shares Aren't Extending Yesterday's Gains

    EV makers in China are still feeling the effects of lockdowns, but a new report today says help may be on the way.

  • Why AMC Entertainment Stock Is Rising Yet Again today

    Shares of AMC Entertainment (NYSE: AMC) were 3.4% higher at 11:24 a.m. ET on Wednesday after the movie theater operator filed a statement with the Securities and Exchange Commission that it now owns a 6.8% stake in National CineMedia (NASDAQ: NCMI), which runs advertisements on movie theater screens. CEO Adam Aron has said he would be making more investments using the $1.8 billion in liquidity AMC has available, and a purchase like this is probably what most people had in mind. National CineMedia is a holding company whose sole purpose is to operate National CineMedia LLC (NCM), which distributes ads to theaters.

  • Musk Mad Tesla Removed from S&P 500 ESG Index

    Tesla ( ) CEO Elon Musk is extremely unhappy that the EV company was eliminated from the S&P 500 ESG Index on Wednesday, voicing his concerns on Twitter. The electric automaker was taken off the ESG index by S&P Dow Jones Indices due to Tesla's ongoing issues of racial discrimination claims from employees and how it has dealt with a National Highway Traffic Safety Administration (NHTSA), a government investigation after several crashes were connected to its autopilot vehicles. The changes are retroactive: they are effective May 2 and a May 17 S&P Dow Jones Indices blog post described the rationale.

  • This Semiconductor Stock Could Go Parabolic

    Applied Materials (NASDAQ: AMAT) stock has lost a quarter of its value on the market in 2022, but shares of the company that supplies semiconductor manufacturing equipment to foundries have been in recovery mode over the past week. It won't be surprising to see Applied Materials stock get a nice shot in the arm when it releases its fiscal 2022 second-quarter results after the market closes on May 19. Applied Materials has won big from the global semiconductor shortage over the past couple of years, consistently logging robust top- and bottom-line growth.

  • Buffett vs. Burry: Who's Right on Apple?

    Warren Buffett is legendary for perhaps the greatest long-term investing performance in history. Michael Burry is legendary in his own right for his shorting the housing market and banks before the financial crisis of 2008, immortalized in the movie The Big Short. Perhaps the most interesting takeaway was that Buffett, or at least someone at his conglomerate Berkshire Hathaway (NYSE: BRK.A) (NYSE: BRK.B), bought even more shares of Apple (NASDAQ: AAPL) last quarter, despite its already being Berkshire's largest position.

  • Why Tesla Stock Fell Again Today

    Shares of electric vehicle (EV) kingpin Tesla (NASDAQ: TSLA) dropped sharply in Wednesday early afternoon trading, falling 5.2% through 12:10 p.m. ET. You can blame two Wall Street analysts for that drop: Piper Sandler and France's Exane BNP Paribas. In twin reports this morning, first Piper Sandler cut its price target on Tesla to $1,035 per share (but maintained its overweight rating), and then Exane BNP Paribas cut its price target on Tesla to $600, and reiterated its underperform (i.e., sell) rating.

  • BlackBerry Provides Long-term Financial Targets

    BlackBerry Limited (NYSE: BB; TSX: BB) today provided its long-term financial targets in connection with its annual analyst summit event.

  • 2 Reasons Why Amazon Stock Is Slumping Today

    Shares of the e-commerce juggernaut Amazon (NASDAQ: AMZN) were falling today as investors processed the disappointing quarterly financial results recently reported from two of Amazon's peers. Additionally, Amazon's stock was tumbling today as investors continued to worry about rising inflation and how the Federal Reserve's action in response to it could slow down the economy. As of 11:39 a.m. ET, Amazon's stock had fallen 5.4%.

  • Amazon Stock Plunges in Wake of Target, Walmart Debacles. This Is Why.

    The trends highlighted by Target's and Walmart's disappointing results bode poorly for Amazon. Investors reacted with shock, sending shares down sharply.